Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

d increased personal and personal related costs for our technical operations. For the year ended December 31, 2008, increased expenses resulted from investments in our development programs, increased medical education activities and increased marketing activities.

Our effective income tax rate was a benefit of 76.3 percent and an expense of 18.0 percent for the quarters ended December 31, 2008 and 2007, respectively and an expense of 22.4 percent and 29.7 percent for the year ended December 31, 2008 and 2007, respectively. Our income tax expense includes federal, state and foreign income taxes at statutory rates and the effects of various permanent differences. The decrease in the 2008 rate as compared to 2007 is primarily due to the impact of the orphan drug credit for maribavir and the decreased level of income before taxes.

Working Capital Highlights

As of December 31, 2008, ViroPharma's working capital was approximately $305.4 million, which represents a $289.0 million decrease from December 31, 2007, caused by a $366.4 million decrease in the fourth quarter of 2008 mainly related to the acquisition of Lev ($380.2 million), offset slightly by operating cash flows. Cash flow from operating activities for the three months and year ended December 31, 2008 was $0.6 million and $91.4 million, respectively.

Business Development Highlights

In October 2008, we completed our acquisition of Lev. Lev was a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. The terms of the merger agreement provided for the conversion of each share of Lev common stock into upfront consideration in the aggregate amount of $442.9 million, or $2.75 per Lev share, comprised of $2.25 per share in cash and $0.50 per share in ViroPharma common stock, and contingent consideration (CVRs) of up
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  Ardelyx, Inc. (NASDAQ: ... focused on cardio-renal, gastrointestinal and metabolic diseases, today ... financial results on Thursday, November 6, 2014. Following ... a live conference call and webcast at 4:30pm ... provide a business update. The live ...
(Date:10/30/2014)... Illinois (PRWEB) October 30, 2014 ... and Cellular Medicine Showcase in Chicago, leading applied ... Orthopedic Surgeon, Dr. Wade McKenna presented talks on ... and Orthopedic Surgical Applications For Stem Cells. , ... amniotic membrane and the properties of AlphaGEMS that ...
(Date:10/30/2014)... 30, 2014 James Sherley says he has ... tissue stem cell technology since his days as a principal ... in the late 1990’s. Sherley founded the ASCTC as ... holds all the intellectual property developed in Sherley’s research over ... Massachusetts Institute of Technology (MIT), and more recently as a ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and the ... fleet of high volume High Pressure Processing (HPP) systems. , ... to PackExpo this year, which is where we first announced ... Williams, CEO at Avure. “Sales of the new Avure machine ... the challenges of market demand for higher throughput. We sold ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... ... attracts investors, COLUMBUS, Ohio, Aug. ... for venture capital investments in biotech innovation and,business growth, according ... markets the state for capital,investment. The report, released by BioEnterprise, ...
... Barr,Pharmaceuticals, Inc. (NYSE: BRL ) today ... a challenge of the patent listed by,Warner Chilcott ... (norethindrone and ethinyl estradiol) chewable oral contraceptive. The,Company ... an Abbreviated New Drug,Application (ANDA) containing a paragraph ...
... Keck Graduate Institute,(KGI) today announced the election of ... M. Burzik, chief executive officer of Kinetic Concepts,Inc.; ... at,Gilead Sciences; and Peter Barton Hutt, senior counsel ... of leaders in business, industry and education who,have ...
Cached Biology Technology:Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry 2Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 2Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 3KGI Elects Three New Members to Board of Trustees 2
(Date:10/30/2014)... help reduce or reverse soil subsidence and reduce ... Sacramento-San Joaquin River Delta by Dartmouth College researchers ... one of the first to continually measure the ... cycle through wetlands, appears in the journal by ... Worldwide, agricultural drainage of organic soils has resulted ...
(Date:10/30/2014)... Philadelphia, PA, October 30, 2014 – Bacteria in ... are critical for digestion. Yet, these same bacteria ... system if they penetrate the gut and enter ... natural response to protect the body, chronic or ... diseases. Prior research has established the involvement of ...
(Date:10/29/2014)... their hair as a consequence of chemotherapy will benefit ... scalp cooling technology that prevents hair loss. , The ... by global scalp cooling manufacturing company, Paxman Coolers, of ... of the University of Huddersfield. , The research will ... a background in the pharmacology of cancer treatment, which ...
Breaking Biology News(10 mins):Dartmouth study finds restoring wetlands can lessen soil sinkage, greenhouse gas emissions 2Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... simple technique to make a common virus-killing material significantly more ... Andrew Barron and Qilin Li. Rather than trying to ... into the public domain. They hope wide adoption will save ... professors and their team reported in Environmental Science and ...
... ITHACA, N.Y. Scientists have identified the genes related ... for planting crops closer together, which has led to an ... Genetics , Jan. 9, 2011.) The study, led ... Agricultural Research Service (USDA-ARS) at Cornell and North Carolina ...
... MD (January 11, 2011)-- The Genetics Society of America ... Research Conference, March 30-April 3, 2011 at the Town ... This annual meeting brings together basic research scientists, ... the common fruit fly, whose hereditary traits Thomas Hunt ...
Cached Biology News:Virus killer gets supercharged 2Virus killer gets supercharged 3Technique allows researchers to identify key maize genes for increased yield 252nd Genetics Society of America Drosophila Research Conference announced 2
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Biology Products: